Proliferative Diabetic Retinopathy Market
Number of pages: 100 | Report Format: PDF | Published date: February 27, 2023
Historical Years – 2020 | Base Year – 2021 | Forecasted Years – 2022-2030
|
Report Attribute |
Details |
|
Market Size Value in 2021 |
US$ 1.8 billion |
|
Revenue Forecast in 2030 |
US$ 3.28 billion |
|
CAGR |
6.9% |
|
Base Year For Estimation |
2021 |
|
Forecast Period |
2022-2030 |
|
Historical Year |
2020 |
|
Segments Covered |
Treatment Type, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, and the Rest of the World (RoW) |
According to the deep-dive market assessment study by Growth Plus Reports, the global proliferative diabetic retinopathy market was valued at US$ 1.8 billion in 2021 and is expected to register a revenue CAGR of 6.9% to reach US$ 3.28 billion by 2030.
Proliferative Diabetic Retinopathy Market Fundamentals
Proliferative diabetic retinopathy (PDR) is an advanced condition of diabetic retinopathy. In PDR, the retina of the eye becomes weak and has difficulty in controlling blood flow resulting in blindness. This condition develops when tiny blood vessel growths called microaneurysms begin to appear on the retina’s surface, weakening the retina and impairing its ability to regulate blood flow. Circulation issues deprive the retina of oxygen. New, delicate blood vessels thus consequently start to form in the retina and the vitreous, a gel-like fluid that fills the back of the eye. The vitreous could become blood-stained from the new blood vessels, impairing vision. The development of glaucoma and the detachment of the retina as a result of the creation of scar tissue are other PDR side effects. An eye condition known as glaucoma causes the optic nerve to progressively deteriorate. In PDR, new blood vessels develop in the region of the eye where the drainage of the eye’s fluid occurs. This causes the eye pressure to increase significantly, which harms the optic nerve. PDR affects around 1.5% of people with diabetes. According to the Diabetic Retinopathy Study, around half of all PDR-affected eyes would experience severe vision loss (visual acuity of 20/800 for at least four months) if untreated.
Any form of treatment aims to prevent or defer the spread of the illness. Nutrition, exercise, and blood sugar management can all slow the disease’s course. Therapy alternatives include laser treatment (photocoagulation). If started before the retina has suffered significant damage, laser treatment typically prevents vision loss extremely well. A more aggressive laser therapy termed scatter (pan-retinal) photocoagulation may be used to treat severe proliferative retinopathy. It enables the physician to control the development of additional blood vessels over the back of the retina. Proliferative retinopathy may not always respond favorably to laser treatment. The development of aberrant blood vessels in the retina is slowed by anti-VEGF medications. Anti-VEGF medications stop VEGF’s effects. If the macula has been harmed by macular edema, an anti-VEGF medication, such as aflibercept (Eyelea) or ranibizumab (Lucentis), may be utilized.
A steroid injection can also be used in the treatment. In some cases, an implant, such as Iluvien, may be injected into the eye. Over time, the implant gradually releases a small amount of corticosteroid. If the retina has not been seriously injured, this operation might improve the vision. This implant procedure is undertaken in cases of bleeding (vitreous hemorrhage) or retinal detachment. Those with early-stage retinopathy rarely experience these two issues.
[6575757]
Proliferative Diabetic Retinopathy Market Dynamics
The rising prevalence of diabetes, the growing geriatric population, and the increasing prevalence of blindness due to diabetes are among the major factors anticipated to boost market revenue growth over the forecast period. The global proliferative diabetic retinopathy market is further propelled by increasing awareness about diabetes management and care and product launches. Increasing patient awareness levels and rising healthcare costs are some additional factors that are anticipated to drive the global proliferative diabetic retinopathy market revenue growth. Additionally, the WHO estimates that the world’s aging population will more than double by 2050, as compared to that in 2020. Diabetes is a serious and rising problem globally, where the inefficiency of the pancreas to produce insulin results in an increase in blood glucose levels. Diabetic retinopathy is caused by damage to the blood vessels in the retina. This leads to blurred vision and vision loss in most cases. The major risk factors for PDR include the duration of diabetes; about 30-34 years of diabetes increase the risk of retinopathy by 65%, according to the reports published by Columbia University. Thus, the prevalence of PDR is rising along with the cases of diabetes, which is a direct cause of this increase.
However, the growth of the global proliferative diabetic retinopathy market is limited by the dearth of skilled ophthalmologists and extended approval time for drugs.
Proliferative Diabetic Retinopathy Market Ecosystem
The global proliferative diabetic retinopathy market has been analyzed from two perspectives: treatment type and region.
Proliferative Diabetic Retinopathy Market by Treatment Type
[8657575]
Based on the treatment type, the global proliferative diabetic retinopathy market has been segmented into anti-VEGF (anti-vascular endothelial growth factor therapy), intraocular steroid, laser surgery, and vitrectomy.
The anti-VEGF therapy segment accounts for the largest revenue share in the global proliferative diabetic retinopathy market. Recent research studies suggest that in cases of PDR, high levels of vascular endothelial growth factors being detected in fibrovascular tissues of the eyes of diabetic patients have prompted the usage of anti-VEGF as the most effective and efficient management method. The International Organization for the Prevention of Blindness estimates that around 70 million (11%) individuals are likely to have diabetic retinopathy, which poses a threat to their ability to see, by 2040. This amounts to around 224 million (35%) people worldwide. Due to effective treatment that improved the visual acuity of patients with PDR, the anti-VEGF agents segment is also predicted to exhibit a similar trend during the forecast period. The rising prevalence of diabetic retinopathy and the availability of advanced technologies are the key driving factors in the anti-VEGF segment.
Intraocular steroidal injection, on the other hand, is a relatively recent treatment for PDR and is gradually gaining popularity. The corticosteroid-based medications in the injections regulate cellular proliferation. Triamcinolone (Durezol) has demonstrated the best therapeutic performance of all corticosteroids under investigation and registers a significant market share. Additional segments discuss using vitrectomy and laser surgery to treat retinopathy.
Proliferative Diabetic Retinopathy Market by Region
Based on the region, the global proliferative diabetic retinopathy market has been segmented into North America, Europe, Asia Pacific, and the rest of the world.
North America accounts for the largest revenue share in the proliferative diabetic retinopathy market. This is driven by the region’s increased access to cutting-edge technology and minimally invasive laser techniques, as well as the rising prevalence of diabetes and diabetic retinopathy. According to the Centers for Disease Control and Prevention (CDC), about 655,000 persons with diabetic retinopathy and approximately 4.2 million adults overall have the condition. The widespread usage of management medications, including the anti-VEGF pharmaceuticals Lucentis, Avastin, and Eylea, has also contributed to the growth of this disease’s therapeutic market in North America. Additionally, rising healthcare costs and the existence of established healthcare infrastructure are both contributing significantly to the growth of the regional industry, as are government-supported reimbursement schemes.
Proliferative Diabetic Retinopathy Market Competitive Landscape
The prominent players operating in the global proliferative diabetic retinopathy market are:
Proliferative Diabetic Retinopathy Market Strategic Developments
The global proliferative diabetic retinopathy market is expected to register growth at a revenue CAGR of 6.9% during the forecast period.
Genentech, Inc., Kubota Vision Inc., Regeneron Pharmaceuticals Inc., Bayer AG, and Alimera Sciences, Inc are among the key players in the global proliferative diabetic retinopathy market.
The anti-VEGF therapy segment dominates the global proliferative diabetic retinopathy market.
Asia Pacific region is expected to observe the highest revenue growth in the global proliferative diabetic retinopathy market during the forecast period.
The global proliferative diabetic retinopathy market was valued at US$ 1.8 billion in 2021.
*Insights on financial performance are subject to the availability of information in the public domain